Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study | Zendy

Maryam Fouladi | Zendy; Clinton F. Stewart | Zendy; Susan M. Blaney | Zendy; Arzu OnarThomas | Zendy; Paula Schaiquevich | Zendy; Roger J. Packer | Zendy; Amar Gajjar | Zendy; Larry E. Kun | Zendy; James M. Boyett | Zendy; Richard J. Gilbertson | Zendy

AI Assistant Blog Pricing

Open Access

Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

Author(s) -

Maryam Fouladi,

Clinton F. Stewart,

Susan M. Blaney,

Arzu OnarThomas,

Paula Schaiquevich,

Roger J. Packer,

Amar Gajjar,

Larry E. Kun,

James M. Boyett,

Richard J. Gilbertson

Publication year - 2010

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.28.4687

Subject(s) - medicine , lapatinib , refractory (planetary science) , oncology , cancer , trastuzumab , breast cancer , astrobiology , physics

To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog